CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China.

MLA

M. Patricia Madigan, et al. “CYP17 Polymorphisms in Relation to Risks of Prostate Cancer and Benign Prostatic Hyperplasia: A Population-Based Study in China.” International Journal of Cancer, vol. 107, no. 2, Nov. 2003, p. 271. EBSCOhost, https://doi.org/10.1002/ijc.11378.

APA

M. Patricia Madigan, Yu-Tang Gao, Jie Deng, Ruth M. Pfeiffer, Bao-Li Chang, Siqun Zheng, Deborah A. Meyers, Frank Z. Stanczyk, Jianfeng Xu, & Ann W. Hsing. (2003). CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China. International Journal of Cancer, 107(2), 271. https://doi.org/10.1002/ijc.11378

Chicago

M. Patricia Madigan, Yu-Tang Gao, Jie Deng, Ruth M. Pfeiffer, Bao-Li Chang, Siqun Zheng, Deborah A. Meyers, Frank Z. Stanczyk, Jianfeng Xu, and Ann W. Hsing. 2003. “CYP17 Polymorphisms in Relation to Risks of Prostate Cancer and Benign Prostatic Hyperplasia: A Population-Based Study in China.” International Journal of Cancer 107 (2): 271. doi:10.1002/ijc.11378.